Serono Nears Settlement In Serostim Investigation, Sets Aside $725 Mil.
Executive Summary
Serono is setting aside $725 mil. to settle federal and state claims related to pricing and marketing practices for the AIDS wasting therapy Serostim (human growth hormone)
You may also be interested in...
Serostim $704 Mil. Settlement Is Largest For Off-Label Marketing Case
Serono's $704 mil. settlement over Serostim promotional practices marks the largest penalty ever paid by a pharmaceutical manufacturer to resolve civil and criminal investigations into off-label marketing
Serostim $704 Mil. Settlement Is Largest For Off-Label Marketing Case
Serono's $704 mil. settlement over Serostim promotional practices marks the largest penalty ever paid by a pharmaceutical manufacturer to resolve civil and criminal investigations into off-label marketing
Serostim Sales Plan Included Physician Kickbacks, Government Alleges
Serono sales managers created a plan offering physicians financial incentives to prescribe Serostim in numbers needed to achieve sales goals, an information filed by Boston U.S. Attorney Michael Sullivan alleges